Navigation Links
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Date:8/28/2008

OSLO, August 28 /PRNewswire-FirstCall/ --

- Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC)

Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose. Pain palliation is an important quality of life benefit in metastatic cancer patients. The trial also confirmed Alpharadin's benign side-effect profile and, importantly for a drug in this clinical setting, no significant bone marrow toxicity was observed.

In men with HRPC life expectancy can be as short as 18 months, and it is estimated that 100,000 men in the EU and USA die from the disease each year. In 85% of these men the tumor will have spread into the bones. These metastases are a significant problem as they can cause intractable and debilitating pain as well as contributing to a further reduction in life expectancy.

The BC1-03 study was a double-blind randomised pain control study comparing the palliative effects of four different single dose levels of Alpharadin in patients with bony metastatic HRPC. The drug was given by i.v. injection mainly on an outpatient basis. The palliative efficacy of Alpharadin was measured using an assessment of bone pain as well as the patient's consumption of analgesia. The primary study objective was to investigate whether there was a dose-response relationship with respect to pain palliation in this patient group. The study has shown the beneficial palliative effect of a single dose of Alpharadin and that there is a clear dose-response effect, with higher doses providing better pain relief.

The study also showed a dose-dependent reduction in bone al
'/>"/>

SOURCE Algeta
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
2. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
3. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
4. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
5. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
8. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
9. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
10. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...wswire/ -- Milk. It does a body good. And,now it,...ter years of,research, scientists at OncoNutritio...k that stimulate the body,s own production of anti... Release, go to:, http://www.prnewswire.com/mnr/eq...w cancer therapies, the chief scientist, Dr. David...
(Date:11/20/2008)...swire/ -- Radius Health ("Radius") announced today...ts second institutional financing round, increasin...he total amount raised since the company,s incepti...nvestors participated in the financing, led by MPM...al, The Wellcome Trust, HealthCare Ventures, Oxfor...
(Date:11/20/2008)... The Scandinavian-based drug,devel...ts of studies on its,lead antimicrobial candidate...he studies showed that the novel lytic peptidomime...ificantly better towards killing Staphylococcus,a...d standard drugs. In,addition to this it has prov...
(Date:11/19/2008)...e statistical significance , , ISELIN, N.J....ration (Nasdaq: PARS ) today announced results f...oEmulsion (NE) drug delivery technology formulated... multi-center, randomized, double-blinded, placebo...y of the Company,s 3% Diclofenac Diethanolamine Na...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Experimental Drug Fights Prostate Cancer 5747 1Experimental Drug Fights Prostate Cancer 5747 2Tweens double use of diabetes drugs 5745 1Tweens double use of diabetes drugs 5745 2Higher levels of pollutants found in fish caught near a coal fired power plant 5743 1Higher levels of pollutants found in fish caught near a coal fired power plant 5743 2HCA Reports Third Quarter 2007 Results 5741 1HCA Reports Third Quarter 2007 Results 5741 2HCA Reports Third Quarter 2007 Results 5741 3HCA Reports Third Quarter 2007 Results 5741 4HCA Reports Third Quarter 2007 Results 5741 5HCA Reports Third Quarter 2007 Results 5741 6HCA Reports Third Quarter 2007 Results 5741 7HCA Reports Third Quarter 2007 Results 5741 8HCA Reports Third Quarter 2007 Results 5741 9HCA Reports Third Quarter 2007 Results 5741 10HCA Reports Third Quarter 2007 Results 5741 11HCA Reports Third Quarter 2007 Results 5741 12HCA Reports Third Quarter 2007 Results 5741 13HCA Reports Third Quarter 2007 Results 5741 14
...NESS WIRE)--Mar 20, 2007 - Arrowhead,Research Corp...y-owned subsidiary Calando Pharmaceuticals has pub...Academy of Sciences,(PNAS) of the first non-human ...h Calando,s lead siRNA therapeutic candidate., Cal...eted,polymeric delivery systems and siRNA design t...
...20, 2007 /PRNewswire/ -- Treatment of,coronary art... the,inpatient setting, according to a study publi..., U.S. hospitalization rates for heart attacks (ac...from 2002 to 2005, possibly due,to broader use of ...irin, as well as declines in risk factors like smo...
Other Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
(Date:11/21/2008)... The Providence Service,...t Craig A. Norris, the Company,s,Chief Operating ... of,Directors. Mr. Norris, appointment fills the...even I. Geringer and returns the board to six memb...of the Board. , Mr. Norris, age 41, has bee...
(Date:11/21/2008)...roved effective against Lennox-Gastaut syndrome ,...new drug called Banzel (rufinamide) has been appro... of epilepsy called Lennox-Gastaut syndrome, the U... , The approval was based on results of a four-... to 30. Compared to patients who took a placebo, t...
(Date:11/21/2008).... 21 New research at W...okeless, spitless tobacco product aimed at young a...nd that RJ Reynolds, Camel Snus - touted as a soci...s surprisingly high levels of nicotine. , , ...r snuff products," said Bruce Adkins of the state ...
(Date:11/21/2008)...1 U.S. News & World...urance (NCQA) ranked BlueChoice(R) HealthPlan of S...ealth Plans(TM), published in U.S. News & Worl...ed annual ranking ranks the nation,s best health p...n and NCQA accreditation scores. NCQA and U.S. New...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...esticides and solvents can further lower fertility...udy shows these chemicals may worsen the effect of...infertility. The authors stress the findings shoul... involved a selected population of infertile men, ...
...communication has always been an effective utility...eo disc is helping patients make important decisio...ld you what treatment to have are long gone. Patie...aking process.// But sometimes this is difficult, ...
...e era where one fights battle towards eternity and...ality and morbidity indicators preclude the exista... result of such on going research , Dr. Simona Gia... Sanita, Rome, and colleagues from the MATISS Proj...
...orks better than massage as a treatment for chroni...ther therapies when used over long periods.That's ...into the effectiveness of the complementary medici... needles into special sites in the nervous system....
Other Medicine News:
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)
...ing of tube racks. Its camera-based vision system ... per rack, making it ideal for use in automated se... rack to be read automatically and can be easily a...prevents a rack from being read in the wrong orien...
Polypropylene workbench top with powder-coated steel legs. Height is adjustable from 25"-34". Available in hundreds of sizes and configurations. Accessories include shelves, drawers, light fixtures a
Perforated or Rod Top, Free Standing or Wall Mounted, Storage Cubby Optional, Polypropylene Construction
Medicine Products: